IVERIC bio

About

IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.

Princeton,New Jersey,United States
101 - 250
https://ivericbio.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $250M
Industries: Biotechnology,Health Care,Pharmaceutical
Founded date: Jan 1, 2007
Number Of Employee: 101 - 250
Operating Status: Active
Stock Symbol: nasdaq:ISEE
Legal Name: IVERIC bio, Inc.
Also Known As: Ophthotech Corporation

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

10

$807.90M

IVERIC bio has raised a total of $807.90M in funding over 2 rounds. Their latest funding was raised on Nov 30, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Nov 30, 2022	Post-IPO Equity	$300M	—	—	—	Detail
Jul 26, 2022	Post-IPO Debt	$250M	2	Hercules Capital Silicon Valley Bank	—	Detail
Jul 13, 2021	Post-IPO Equity	$100.20M	—	—	—	Detail
Jan 1, 2020	Post-IPO Equity	—	1	—	—	Detail
Jan 24, 2014	Post-IPO Equity	$41.70M	1	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

8

IVERIC bio is funded by 8 investors. Hercules Capital and Silicon Valley Bank are the most recent investors.

Investor Name	Lead Investor	Funding Round
Hercules Capital	Yes	Post-IPO Debt
Silicon Valley Bank	Yes	Post-IPO Debt
Sofinnova Investments	Yes	Series Unknown
Clarus Ventures	Yes	Series B
Frazier Healthcare Partners	—	Post-IPO Equity
Novo Holdings	—	Post-IPO Equity
HBM Healthcare Investments AG	—	Series B
SV Health Investors	—	Series B